Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Garufi

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysisS Giacchetti, P A Dugué, P F Innominato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)C Pinto, F Di Fabio, E Maiello, et al.
Breast Cancer Research and Treatment|June 1, 2000
Weekly schedule of vinorelbine in pretreated breast cancer patientsC Nisticò, C Garufi, M Milella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2012
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?D Santini, B Vincenzi, R Addeo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?D Santini, B Vincenzi, R Addeo, et al.
ESMO Open|January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trialF Piscaglia, G Masi, E Martinelli, et al.
In Vivo (Athens, Greece)|January 6, 2007
A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response ratesR Mancini, L Carpanese, R Sciuto, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysisS Giacchetti, P A Dugué, P F Innominato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)C Pinto, F Di Fabio, E Maiello, et al.
Breast Cancer Research and Treatment|June 1, 2000
Weekly schedule of vinorelbine in pretreated breast cancer patientsC Nisticò, C Garufi, M Milella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2012
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?D Santini, B Vincenzi, R Addeo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?D Santini, B Vincenzi, R Addeo, et al.
ESMO Open|January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trialF Piscaglia, G Masi, E Martinelli, et al.
In Vivo (Athens, Greece)|January 6, 2007
A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response ratesR Mancini, L Carpanese, R Sciuto, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
Pageof 6